Study links weight-loss drugs to serious eye conditions and vision loss
One study, published in JAMA, assessed data from nearly 1.5 million people and found that there was an increased risk of optic nerve disorders in people with diabetes taking medication such as semaglutide or tirzepatide.
The research specifically flags a rare but devastating condition called non-arteritic anterior ischaemic optic neuropathy, or NAION, wherein blood flow to the optic nerve is suddenly reduced or blocked, leading to an 'eye stroke'. Patients notice it only after they lose vision in one eye, researchers write in The Conversation.
There is no treatment for the condition.
A previous study noted there was a one in 10,000 chance of a patient developing NAION as a side effect of semaglutide medication. But the latest research found that 35 of the 159,000 people with type 2 diabetes taking semaglutide or tirzepatide – about 1 in 2,500 – developed NAION.
'During the two-year follow-up, there were 35 patients with NAION in the semaglutide or tirzepatide group,' the researchers said. 'There were 93 patients with other optic nerve disorders.'
Another large study of 185,000 people, published in the same journal, links weight-loss drugs known as GLP-1 RAs to an elevated risk of diabetic retinopathy, which refers to blood vessels in the retina getting damaged.
Participants on GLP-1 drugs in both studies, however, saw fewer vision-threatening complications from diabetic retinopathy and required less invasive eye treatments compared to those taking other diabetes medications, the researchers noted.
Although researchers say the overall risk of developing such conditions from taking the drugs is low, they call for closer monitoring.
They also call for further long-term studies to understand how weight-loss drugs can lead to eye complications.
'The cost of GLP-1 RAs must be weighed against the potential of these agents to lower the costs associated with the treatment of diabetes and its complications,' researchers said.
The latest research suggests that all diabetes patients given weight-loss drugs, regardless of pre-existing diabetic retinopathy, should be regularly screened and monitored for potential complications.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Breakthrough therapy helps worst chronic low back pain sufferers feel better... and it lasts for years
A groundbreaking therapy that encourages back pain patients to slowly take on movements they fear or that trigger pain, could relieve their suffering for at least three years, a study suggests. Researchers in Australia asked nearly 500 patients with chronic lower back pain that limited their daily movements to undergo cognitive functional therapy (CFT) for three months. The therapy involved participants describing their pain to doctors to help understand its causes, followed by gradually attempting movements that caused discomfort in order to build confidence and equip them with strategies to better manage their pain. Over the first three months, participants who tried the therapy reported significant improvements in movement and pain compared to those who relied on typical care, such as over-the-counter painkillers and surgeries. After three years, those who received CFT were still reporting lower pain levels and fewer limits on movement than those who received typical care. Dr Matt Hancock, a physiotherapist at Macquarie University who led the study, said: 'CFT is the first treatment for chronic disabling low back pain with good evidence of large, long-term (over 12 months) effects on disability. 'It offers a high-value, low-risk intervention with long-term benefits for patients with persistent, disabling low back pain.' The researchers are now calling on doctors to begin recommending the therapy for all patients, calling it a cost-effective method of relieving back pain. An estimated 75 to 85 percent of Americans experience back pain at some point during their lifetimes, while 25million currently suffer from lower back pain. Doctors normally treat the pain, which can be caused by sprains, arthritis and traumatic injuries, with over-the-counter painkillers, physical therapy and, in some cases, surgery. Patients have also been offered talk therapy since 2017, with doctors referring some patients for cognitive behavioral therapy (CBT). With CBT, patients attempt to reconceptualize their pain in order to reduce it. Pain reductions from this tend to be short-lived, however. In the new study, scientists recruited patients who had been suffering from moderate back pain who said it limited their day-to-day activities, such as causing them to move slowly or struggle to pick up heavy objects. Participants were 47 years old on average, overweight and said they had been seeking care for the pain for four years. They were asked to attend 20 clinics in Perth and Sydney, Australia, to receive treatment between October 2018 and August 2020 and split into three groups. The first received CFT, the second received CFT plus biofeedback, where sensors are used to map movements, and the third received typical care, or followed the care plan recommended by their doctor. Participants in both CFT groups attended seven treatment sessions over three months and a booster session at six months. Each session lasted 60 minutes and was led by a physical therapist. In the CFT sessions, participants were first encouraged to share the story of their pain to help them understand their discomfort and its underlying causes. They were then guided through movements and activities that they previously said were painful, feared or avoided, to help them learn how to manage the pain. At the end of the sessions, patients also received lifestyle guidance on healthy habits such as the need for regular physical activity, improved sleep, diet and regular socializing. In the initial study, published in The Lancet Rheumatology, all participants had a moderate level of disability from back pain. Three years later, however, in the groups that received CFT this had dropped to and remained at a mild level of disability, when back pain causes some limitations but does not impair overall function. Those with mild impairment may be able to walk around with little difficulty but can still struggle to lift heavy objects. There was no significant difference between the groups that received CFT only and those that received CFT and biofeedback. In the group continuing typical care, however, people still experienced a moderate level of disability. A moderate level of disability suggests participants can move only a short distance before requiring a break and can still perform basic daily activities like dressing or cooking but may take longer than usual. The study was first revealed in 2023 but was republished again this month with updated data from three years after the study began, showing that the therapy could reduce pain for three years. The scientists said CFT boosted participants' movement and reduced their pain because it reduced their fear of certain actions that had caused pain and made them less likely to avoid these behaviors. They said the course was also carried out by trained therapists and had a booster session six months later, which ensured patients got better training. In the latest paper, the researchers said: 'CFT produces clinically important effects for activity limitation at three-year follow-up.
BBC News
an hour ago
- BBC News
'NHS cut funding after Gran didn't die on time'
A woman has accused the NHS of withdrawing funding for her 98-year-old grandmother's care because "she didn't die on time".Pearl, from Bradford, has advanced dementia and was fast-tracked onto NHS Continuing Healthcare (CHC) in 2023 to support her at home after a hospital granddaughter, Kirstie Lumley, said she was now being left to "die without dignity" after funding was stopped when a review found her needs were no longer primarily West Yorkshire Integrated Care Board (WYICB) acknowledged its funding decisions could cause "disappointment and distress" but added they were "based on an individual's assessed needs, not their diagnosis or financial situation". In June 2023, Pearl's family were told she required end-of-life care after being discharged from hospital following a urinary tract the time she was deemed eligible for fast track CHC, which allows quick access to NHS funding for patients who have a "rapidly deteriorating condition" and "may be entering a terminal phase".Last month, following a review of her case, the family was told that funding would cease on 1 August Lumley, from Malton, North Yorkshire, said the decision felt "unfair" because her grandmother's condition was "certainly no better" than when she was originally funded."She was expected to pass away in 2023 when she was discharged from hospital with an estimated prognosis of six weeks," she said."Because she's outlived that by a huge period of time, it's like she hasn't ticked the box and died on time." Pearl had been receiving 86 hours of NHS-funded care each week, which her family had been topping up with an extra 14 hours of care paid for Council, which has now taken over responsibility, has said she will receive just over 19 hours a week, which the family will have to pay towards, meaning they can no longer afford extra private also means Pearl will no longer have a carer to sit with her overnight and will instead have one 30-minute visit for toilet the changes, she has already fallen out of bed once in the middle of the night, requiring paramedics to be called."She's scared, she's upset, she's confused," Ms Lumley said."Knowing that she might be in that state and be upset and shouting out for help for another five or six hours until a carer arrives, who will only be with her for half an hour, it's just heartbreaking," she said. NHS data shows that at the end of March 2025 more than 51,000 patients in England were eligible for CHC, with almost a third qualifying via the fast track guidance states there may be situations where it is "appropriate to review eligibility" for fast track CHC but goes on to say that where a patient is "expected to die in the very near future" the ICB should continue to take responsibility for the care UK has launched a Fix the Funding campaign, which is calling on the government to urgently review the assessment process for CHC, which it believes is flawed and does not recognise the needs of people with Pike, deputy director of campaigns, said: "For people living with dementia CHC can be an absolute lifeline, but some people will end up living in situations where they may spend the last few years of caring for somebody trying to fight the system."We've had it described to us as 'wading through treacle' in order to try and get the outcome you want, rather than spending that time with the person you love."The Department of Health and Social Care said responsibility for decisions about CHC funding lay with Local Integrated Care Boards, but as part of its 10 Year Health Plan it would be moving more healthcare out of hospitals and into the community, to ensure patients could access the care they needed. 'Disappointment and distress' Meanwhile, a spokesperson for WYICB said: "We have a responsibility to ensure that continuing healthcare decisions are fair, transparent and based on assessed need in accordance with the National Framework for NHS Continuing Healthcare and NHS-funded Nursing Care."Decisions are based on NHS continuing healthcare assessments that are carried out by trained professionals using a nationally defined process."Decisions are based on an individual's assessed needs, not their diagnosis or financial situation."These assessments often involve people who are frail or have multiple needs, with families and carers providing considerable support."We appreciate that continuing healthcare decisions can be significant for individuals and families, especially in complex and sensitive circumstances, with outcomes potentially causing some disappointment and distress."While we cannot comment on individual cases, we can confirm that we are reviewing the matters raised here in line with our policy and complaints process."
Daily Mail
2 hours ago
- Daily Mail
Man accidentally poisons himself after following diet recommended by ChatGPT that made him hallucinate
A man in Washington accidentally poisoned himself after following a diet made by ChatGPT. The unnamed man, 60, rushed to his local emergency room with suspicions that his neighbor was poisoning him. About a day after being admitted to the hospital, he also suffered paranoia and hallucinations and attempted to escape from the hospital. The man later revealed he had several dietary restrictions, including distilling his own water and following an 'extremely restrictive' vegetarian diet. He told doctors after reading about the harms of sodium chloride, or table salt, he asked ChatGPT about eliminating it from his diet. The chatbot reportedly advised him it was safe to replace salt with sodium bromide, which was used as a sedative in the early 20th century and is now found in anticonvulsants for dogs and humans. He ended up following this recommendation for three months and eventually developed bromism, or bromide poisoning. Bromide can accumulate in the body and impair nerve function, a condition called bromism. This leads to confusion, memory loss, anxiety, delusions, rashes and acne, which the man also had. Doctors treating the man, from the University of Washington in Seattle, replicated his search and got the same incorrect advice. They warned that the case highlighted 'how the use of artificial intelligence can potentially contribute to the development of preventable adverse health outcomes.' They said ChatGPT and other chatbots could 'generate scientific inaccuracies, lack the ability to critically discuss results, and ultimately fuel the spread of misinformation.' The anonymous case study, published earlier this month in the Annals of Internal Medicine, comes one week after OpenAI claimed one of the chatbot's newest upgrades could be better at answering health-related questions and 'flagging potential concerns.' However, ChatGPT's guidelines state it is not 'intended for use in the diagnosis or treatment of any health condition.' The patient appeared to have an earlier version of the software. After attempting to escape from the hospital, the man was put on an involuntary psychiatric hold and given large amounts of fluids and electrolytes to help flush the bromide out of his system. His bromide level was at 1,700 mg/L, while the normal range is between 0.9 and 7.3 mg/L. Bromide was used as a sedative in the 19th and 20th centuries and was once widespread in prescription and over-the-counter drugs. However, as research uncovered the risk of chronic exposure, regulators gradually began removing them from the US drug supply. As a result, cases today remain few and far between. The man reported acne and small red growths on his skin, insomnia, fatigue, muscle coordination issues and excessive thirst. It took three weeks for his bromide levels to stabilize and for him to be weaned off psychiatric medications before he was able to be discharged. The doctors treating him wrote: 'While it is a tool with much potential to provide a bridge between scientists and the nonacademic population, AI also carries the risk for promulgating decontextualized information. 'It is highly unlikely that a medical expert would have mentioned sodium bromide when faced with a patient looking for a viable substitute for sodium chloride.' They also emphasized that 'as the use of AI tools increases, providers will need to consider this when screening for where their patients are consuming health information.'
